JP2019503386A - 免疫療法を増強するためのヒストンデアセチラーゼ阻害剤の使用 - Google Patents

免疫療法を増強するためのヒストンデアセチラーゼ阻害剤の使用 Download PDF

Info

Publication number
JP2019503386A
JP2019503386A JP2018539087A JP2018539087A JP2019503386A JP 2019503386 A JP2019503386 A JP 2019503386A JP 2018539087 A JP2018539087 A JP 2018539087A JP 2018539087 A JP2018539087 A JP 2018539087A JP 2019503386 A JP2019503386 A JP 2019503386A
Authority
JP
Japan
Prior art keywords
entinostat
inhibitor
phenyl
methyl
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018539087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019503386A5 (https=
Inventor
ロベルト ピリ
ロベルト ピリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of JP2019503386A publication Critical patent/JP2019503386A/ja
Publication of JP2019503386A5 publication Critical patent/JP2019503386A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2018539087A 2016-01-28 2017-01-27 免疫療法を増強するためのヒストンデアセチラーゼ阻害剤の使用 Pending JP2019503386A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662288121P 2016-01-28 2016-01-28
US62/288,121 2016-01-28
PCT/US2017/015389 WO2017132536A1 (en) 2016-01-28 2017-01-27 Use of histone deacetylase inhibitors for enhancing immunotherapies

Publications (2)

Publication Number Publication Date
JP2019503386A true JP2019503386A (ja) 2019-02-07
JP2019503386A5 JP2019503386A5 (https=) 2020-03-05

Family

ID=58010402

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018539087A Pending JP2019503386A (ja) 2016-01-28 2017-01-27 免疫療法を増強するためのヒストンデアセチラーゼ阻害剤の使用

Country Status (13)

Country Link
US (1) US10813919B2 (https=)
EP (1) EP3407913A1 (https=)
JP (1) JP2019503386A (https=)
KR (1) KR20180104122A (https=)
CN (1) CN108883179A (https=)
AU (1) AU2017211383A1 (https=)
BR (1) BR112018015291A2 (https=)
CA (1) CA3013047A1 (https=)
IL (1) IL260765A (https=)
MX (1) MX2018009247A (https=)
RU (1) RU2018130831A (https=)
WO (1) WO2017132536A1 (https=)
ZA (1) ZA201805066B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020525758A (ja) * 2017-06-04 2020-08-27 ラパポート・ファミリー・インスティテュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシーズＲａｐｐａｐｏｒｔ Ｆａｍｉｌｙ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｒｅｓｅａｒｃｈ ｉｎ ｔｈｅ Ｍｅｄｉｃａｌ Ｓｃｉｅｎｃｅｓ 免疫チェックポイント阻害薬によるがん治療に対する個別化応答の予測方法およびそのためのキット
JP2022548507A (ja) * 2019-09-04 2022-11-21 クリスタルジェノミクス・インコーポレイテッド Ｈｄａｃ阻害剤と抗ｐｄ－１抗体または抗ｐｄ－ｌ１抗体とを含む薬学組成物
US12016900B2 (en) 2017-06-04 2024-06-25 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent
US12070489B2 (en) 2018-12-12 2024-08-27 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with a cancer therapy in combination with another therapeutic agent

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN110300599B (zh) 2016-12-07 2024-07-02 艾吉纳斯公司 抗体和其使用方法
IL264068B2 (en) * 2018-01-05 2023-07-01 Great Novel Therapeutics Biotech & Medicals Corp Aggregate and pharmaceutical preparation containing an hdac inhibitor and an nsaid aggregate together with an immune checkpoint inhibitor for use in a method for removing immunosuppression in the microenvironment of a tumor or stimulating an immune system against cancer cells
CN111836636A (zh) * 2018-01-12 2020-10-27 维拉克塔治疗公司 用于细胞免疫疗法的表观遗传修饰剂
CN112569360A (zh) * 2019-09-30 2021-03-30 中国医学科学院药物研究所 一种基于阻断pd-1/pd-l1的抗肿瘤药物组合物及其应用
WO2023017525A1 (en) 2021-08-11 2023-02-16 OncoHost Ltd. Predicting patient response
EP4705341A1 (en) * 2023-05-05 2026-03-11 Euro-Celtique S.A. Combinations for treating cancer
WO2024238811A2 (en) * 2023-05-18 2024-11-21 Avstera Therapeutics Corp. Composition comprising hdac inhibitor and immune checkpoint inhibitor and methods for using the same
US12553903B2 (en) 2023-06-01 2026-02-17 Cg Pharmaceuticals, Inc Ivaltinostat combination therapy for treating pancreatic cancer
WO2025155922A1 (en) * 2024-01-19 2025-07-24 The Trustees Of Indiana University Hdac3 inhibitors to treat arrhythmogenic cardiomyopathy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157162A1 (en) * 2014-04-06 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase as a modulator of pdl1 expression and activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101523391B1 (ko) 2006-12-27 2015-05-27 에모리 유니버시티 감염 및 종양 치료를 위한 조성물 및 방법
ES2986548T3 (es) * 2015-03-20 2024-11-11 Syndax Pharmaceuticals Inc Combinación de inhibidor de HDAC y anticuerpo anti-PD-1 para el tratamiento del cáncer, en donde la combinación no comprende 5-azacitidina
US20180250320A1 (en) 2015-08-26 2018-09-06 The Johns Hopkins University Compositions and methods for treating solid tumors
BR112018003238A2 (en) * 2015-09-02 2018-09-25 Syndax Pharmaceuticals, Inc. patient selection for combination therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157162A1 (en) * 2014-04-06 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase as a modulator of pdl1 expression and activity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
INTERNATIONAL IMMUNOLOGY, vol. 21, no. 9, JPN6021002558, 2009, pages 1065 - 1077, ISSN: 0004607843 *
JOURNAL OF CLINICAL ONCOLOGY, vol. 33, no. 13, JPN6021002557, 2015, pages 1430 - 1437, ISSN: 0004607842 *
PLOS ONE, vol. Vol.7, Issue 1, JPN6021002556, 2012, pages 30815 - 14, ISSN: 0004607841 *
PNAS, vol. 111, no. 32, JPN6021002559, 2014, pages 11774 - 11779, ISSN: 0004607840 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020525758A (ja) * 2017-06-04 2020-08-27 ラパポート・ファミリー・インスティテュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシーズＲａｐｐａｐｏｒｔ Ｆａｍｉｌｙ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｒｅｓｅａｒｃｈ ｉｎ ｔｈｅ Ｍｅｄｉｃａｌ Ｓｃｉｅｎｃｅｓ 免疫チェックポイント阻害薬によるがん治療に対する個別化応答の予測方法およびそのためのキット
JP2023065523A (ja) * 2017-06-04 2023-05-12 ラパポート・ファミリー・インスティテュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシーズ 免疫チェックポイント阻害薬によるがん治療に対する個別化応答の予測方法およびそのためのキット
US12016900B2 (en) 2017-06-04 2024-06-25 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent
US12070489B2 (en) 2018-12-12 2024-08-27 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with a cancer therapy in combination with another therapeutic agent
JP2022548507A (ja) * 2019-09-04 2022-11-21 クリスタルジェノミクス・インコーポレイテッド Ｈｄａｃ阻害剤と抗ｐｄ－１抗体または抗ｐｄ－ｌ１抗体とを含む薬学組成物
JP7644988B2 (ja) 2019-09-04 2025-03-13 クリスタルジェノミクス・インコーポレイテッド Ｈｄａｃ阻害剤と抗ｐｄ－１抗体または抗ｐｄ－ｌ１抗体とを含む薬学組成物

Also Published As

Publication number Publication date
MX2018009247A (es) 2019-03-11
IL260765A (en) 2018-10-31
US20190030011A1 (en) 2019-01-31
WO2017132536A1 (en) 2017-08-03
US10813919B2 (en) 2020-10-27
CA3013047A1 (en) 2017-08-03
EP3407913A1 (en) 2018-12-05
RU2018130831A (ru) 2020-03-02
AU2017211383A1 (en) 2018-08-16
RU2018130831A3 (https=) 2020-04-23
BR112018015291A2 (pt) 2018-12-18
KR20180104122A (ko) 2018-09-19
ZA201805066B (en) 2019-05-29
CN108883179A (zh) 2018-11-23

Similar Documents

Publication Publication Date Title
US10813919B2 (en) Use of histone deacetylase inhibitors for enhancing immunotherapies
JP6377632B2 (ja) 幹細胞の免疫制御作用を調節する方法
Ridnour et al. NOS inhibition modulates immune polarization and improves radiation-induced tumor growth delay
JP6803339B2 (ja) 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
CN114286681A (zh) Nad+和/或nad+抑制剂和/或nad+激动剂的用途及其联合制剂
Wang et al. LBH589 enhances T cell activation in vivo and accelerates graft-versus-host disease in mice
JP7233220B2 (ja) Ｈｄａｃ阻害剤とｂｅｔ阻害剤の使用方法及びその薬学的組み合わせ
Sarkar et al. The plasticity of immune cell response complicates dissecting the underlying pathology of multiple sclerosis
US20230137723A1 (en) Mesenchymal stem cells for the prevention and targeted treatment of cancer and other disorders
KR20170124467A (ko) 저산소 조건을 이용한 면역세포의 증식 배양 방법
ES2789574T3 (es) Modulación de la activación del inflamasoma de células supresoras derivadas de mieloides para el tratamiento de GvHD o tumor
US20230158112A1 (en) Targeting gamma-delta T Cells in Obesity and Cachexia
CN104138391B (zh) 间充质干细胞在预防或治疗应激反应导致的免疫力下降中的应用
US20240366954A1 (en) Compositions, systems, and methods for treating cancer using tumor treating fields and killer cells
CN114341346A (zh) 用于治疗骨关节炎的治疗性凋亡细胞
EP3911328A1 (en) Fibroblasts and microvesicles thereof for reduction of toxicity associated with cancer immunotherapy
Ma et al. Absence of Stat1 in donor CD4+ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice
WO2018160625A1 (en) Prostacyclin, prostacyclin analogs, and methods of treating or preventing rejection of solid organ transplants
WO2017205779A2 (en) Compositions and methods for treating disorders related to inflammasome activity and il-1alpha expression
WO2024196812A1 (en) Mesenchymal stem cell-derived micro-ribonucleic acid-mediated treatments for the prevention and targeted treatment of cancer and other disorders
WO2025076042A1 (en) Mesenchymal stem cell-mediated treatments for the prevention and targeted treatment of injured tissues and promotion of tissue repair, healing, and regeneration
WO2023146860A1 (en) Compositions for and methods of treating a subject having inflammation
JPH05124957A (ja) インタ−ロイキン−６作用抑制剤
Levescot et al. IL-1β-driven osteoclastogenic T regulatory cells accelerate bone erosion in arthritis
CN113226341A (zh) 用于治疗败血症的早期凋亡细胞

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211005